Acute and non-acute effects of cannabis on human memory function: A critical review of neuroimaging studies

Current Pharmaceutical Design

Volumn 20, Issue 13, 2014, Pages 2114-2125

  Bossong, Matthijs G ^a   Jager, Gerry ^b   Bhattacharyya, Sagnik ^a   Allen, Paul ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b WAGENINGEN UNIVERSITY   (Netherlands)

Author keywords

Brain function; Cannabis; Cognition; Endocannabinoid system; Memory; Neuroimaging; Psychiatric disorders; 9 tetrahydrocannabinol (THC)

Indexed keywords

CANNABIS; ENDOCANNABINOID;

ALZHEIMER DISEASE; BRAIN REGION; CANNABIS SMOKING; COGNITION; COGNITIVE DEFECT; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HUMAN; LEARNING DISORDER; MEMORY; MEMORY DISORDER; MENTAL DISEASE; NEUROIMAGING; NEUROPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA; SPATIAL MEMORY; TASK PERFORMANCE; VERBAL MEMORY; WORKING MEMORY; ADOLESCENT; ADULT; BRAIN; DRUG EFFECTS; NUCLEAR MAGNETIC RESONANCE IMAGING; PROCEDURES; TOXICITY;

ADOLESCENT; ADULT; BRAIN; CANNABIS; HUMANS; MAGNETIC RESONANCE IMAGING; MEMORY; NEUROIMAGING;

EID: 84903700524     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/13816128113199990436     Document Type: Review

References (114)

1. United Nations Office on Drugs and Crime. World drug report 2012. New York, United States: United Nations 2012.
2. European Monitoring Centre for Drugs and Drug Addiction. Annual report 2011: The state of the drugs problem in Europe. Lisbon, Portugal: European Monitoring Centre for Drugs and Drug Addiction 2011.
3. Monshouwer K, Smit F, de Graaf R, van Os J, Vollebergh W. First cannabis use: does onset shift to younger ages? Findings from 1988 to 2003 from the Dutch National School Survey on Substance Use. Addiction 2005; 100: 963-70.
4. Ledent C, Valverde O, Cossu G, et al. Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice. Science 1999; 283: 401-4.
5. Huestis MA, Gorelick DA, Heishman SJ, et al. Blockade of effects of smoked marijuana by the CB1-selective cannabinoid receptor antagonist SR141716. Arch Gen Psychiatry 2001; 58: 322-8.
6. Heifets BD, Castillo PE. Endocannabinoid signaling and long-term synaptic plasticity. Annu Rev Physiol 2009; 71: 283-306.
7. Kano M, Ohno-Shosaku T, Hashimotodani Y, Uchigashima M, Watanabe M. Endocannabinoid-mediated control of synaptic transmission. Physiol Rev 2009; 89: 309-80.
8. Katona I, Freund TF. Multiple functions of endocannabinoid signaling in the brain. Annu Rev Neurosci 2012; 35: 529-58.
9. Herkenham M, Lynn AB, Johnson MR, Melvin LS, De Costa BR, Rice KC. Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J Neurosci 1991; 11: 563-83.
10. Glass M, Dragunow M, Faull RL. Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain. Neuroscience 1997; 77: 299-318.
11. Wong DF, Kuwabara H, Horti AG, et al. Quantification of cerebral cannabinoid receptors subtype 1 (CB1) in healthy subjects and schizophrenia by the novel PET radioligand [11C]OMAR. Neuroimage 2010; 52: 1505-13.
12. Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 1993; 365: 61-5.
13. Devane WA, Hanus L, Breuer A, et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 1992; 258: 1946-9.
14. Sugiura T, Kondo S, Sukagawa A, et al. 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem Biophys Res Commun 1995; 215: 89-97.
15. Stella N, Schweitzer P, Piomelli D. A second endogenous cannabinoid that modulates long-term potentiation. Nature 1997; 388: 773-8.
16. Green B, Kavanagh DJ, Young RM. Reasons for cannabis use in men with and without psychosis. Drug Alcohol Rev 2004; 23: 445-53.
17. Ashton CH. Pharmacology and effects of cannabis: a brief review. Br J Psychiatry 2001; 178: 101-6.
18. Hall W, Degenhardt L. Adverse health effects of non-medical cannabis use. Lancet 2009; 374: 1383-91.
19. Ranganathan M, D'Souza DC. The acute effects of cannabinoids on memory in humans: a review. Psychopharmacology (Berl) 2006; 188: 425-44.
20. Gonzalez R. Acute and non-acute effects of cannabis on brain functioning and neuropsychological performance. Neuropsychol Rev 2007; 17: 347-61.
21. Grant I, Gonzalez R, Carey CL, Natarajan L, Wolfson T. Nonacute (residual) neurocognitive effects of cannabis use: a metaanalytic study. J Int Neuropsychol Soc 2003; 9: 679-89.
22. Jager G, Ramsey NF. Long-Term Consequences of Adolescent Cannabis Exposure on the Development of Cognition, Brain Structure and Function: An Overview of Animal and Human Research. Current Drug Abuse Reviews 2008; 1: 114-23.
23. Schweinsburg AD, Brown SA, Tapert SF. The Influence of Marijuana Use on Neurocognitive Functioning in Adolescents. Current Drug Abuse Reviews 2008; 1: 99-111.
24. Ehrenreich H, Rinn T, Kunert HJ, et al. Specific attentional dysfunction in adults following early start of cannabis use. Psychopharmacology (Berl) 1999; 142: 295-301.
25. Pope HG, Jr., Gruber AJ, Hudson JI, Cohane G, Huestis MA, Yurgelun- Todd D. Early-onset cannabis use and cognitive deficits: what is the nature of the association? Drug Alcohol Depend 2003; 69: 303-10.
26. Harvey MA, Sellman JD, Porter RJ, Frampton CM. The relationship between non-acute adolescent cannabis use and cognition. Drug Alcohol Rev 2007; 26: 309-19.
27. Meier MH, Caspi A, Ambler A, et al. Persistent cannabis users show neuropsychological decline from childhood to midlife. Proc Natl Acad Sci U S A 2012; 109: E2657-64.
28. Green MF. What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry 1996; 153: 321-30.
29. Robbins TW, Ersche KD, Everitt BJ. Drug addiction and the memory systems of the brain. Ann N Y Acad Sci 2008; 1141: 1-21.
30. Marazziti D, Consoli G, Picchetti M, Carlini M, Faravelli L. Cognitive impairment in major depression. Eur J Pharmacol 2010; 626: 83-6.
31. Maldonado R, Valverde O, Berrendero F. Involvement of the endocannabinoid system in drug addiction. Trends Neurosci 2006; 29: 225-32.
32. Leweke FM, Koethe D. Cannabis and psychiatric disorders: it is not only addiction. Addict Biol 2008; 13: 264-75.
33. Bossong MG, Niesink RJ. Adolescent brain maturation, the endogenous cannabinoid system and the neurobiology of cannabisinduced schizophrenia. Prog Neurobiol 2010; 92: 370-85.
34. Hill MN, Hillard CJ, Bambico FR, Patel S, Gorzalka BB, Gobbi G. The therapeutic potential of the endocannabinoid system for the development of a novel class of antidepressants. Trends Pharmacol Sci 2009; 30: 484-93.
35. Moore TH, Zammit S, Lingford-Hughes A, et al. Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet 2007; 370: 319-28.
36. Linszen DH, Dingemans PM, Lenior ME. Cannabis abuse and the course of recent-onset schizophrenic disorders. Arch Gen Psychiatry 1994; 51: 273-9.
37. Foti DJ, Kotov R, Guey LT, Bromet EJ. Cannabis use and the course of schizophrenia: 10-year follow-up after first hospitalization. Am J Psychiatry 2010; 167: 987-93.
38. Rais M, Cahn W, van Haren N, et al. Excessive brain volume loss over time in cannabis-using first episode schizophrenia patients. Am J Psychiatry 2008; 165: 490-6.
39. Chang L, Chronicle EP. Functional imaging studies in cannabis users. Neuroscientist 2007; 13: 422-32.
40. Martin-Santos R, Fagundo AB, Crippa JA, et al. Neuroimaging in cannabis use: a systematic review of the literature. Psychol Med 2010; 40: 383-98.
41. Bhattacharyya S, Crippa JA, Martin-Santos R, Winton-Brown T, Fusar-Poli P. Imaging the neural effects of cannabinoids: current status and future opportunities for psychopharmacology. Curr Pharm Des 2010; 15: 2603-14.
42. Bhattacharyya S, Fusar-Poli P, Borgwardt S, et al. Modulation of mediotemporal and ventrostriatal function in humans by Delta9- tetrahydrocannabinol: a neural basis for the effects of Cannabis sativa on learning and psychosis. Arch Gen Psychiatry 2009; 66: 442-51.
43. Callicott JH, Bertolino A, Mattay VS, et al. Physiological dysfunction of the dorsolateral prefrontal cortex in schizophrenia revisited. Cereb Cortex 2000; 10: 1078-92.
44. Jansma JM, Ramsey NF, van der Wee NJ, Kahn RS. Working memory capacity in schizophrenia: a parametric fMRI study. Schizophr Res 2004; 68: 159-71.
45. Iannetti GD, Wise RG. BOLD functional MRI in disease and pharmacological studies: room for improvement? Magn Reson Imaging 2007; 25: 978-88.
46. Bossong MG, Jager G, van Hell HH, et al. Effects of delta9- tetrahydrocannabinol administration on human encoding and recall memory function: a pharmacological FMRI study. J Cogn Neurosci 2012; 24: 588-99.
47. Bossong MG, Jansma JM, van Hell HH, et al. Effects of delta9- tetrahydrocannabinol on human working memory function. Biol Psychiatry 2012; 71: 693-9.
48. Henson RN, Rugg MD, Shallice T, Josephs O, Dolan RJ. Recollection and familiarity in recognition memory: An event-related functional magnetic resonance imaging study. Journal of Neuroscience 1999; 19: 3962-72.
49. Lundstrom BN, Petersson KM, Andersson J, Johansson M, Fransson P, Ingvar M. Isolating the retrieval of imagined pictures during episodic memory: Activation of the left precuneus and left prefrontal cortex. Neuroimage 2003; 20: 1934-43.
50. Gilboa A, Winocur G, Grady CL, Hevenor SJ, Moscovitch M. Remembering our past: Functional neuroanatomy of recollection of recent and very remote personal events. Cerebral Cortex 2004; 14: 1214-25.
51. Grotenhermen F. Pharmacokinetics and pharmacodynamics of cannabinoids. Clin Pharmacokinet 2003; 42: 327-60.
52. Agurell S, Halldin M, Lindgren JE, et al. Pharmacokinetics and metabolism of delta1-tetrahydrocannabinol and other cannabinoids with emphasis on man. Pharmacol Rev 1986; 38: 21-43.
53. D'Souza DC, Ranganathan M, Braley G, et al. Blunted psychotomimetic and amnestic effects of delta-9-tetrahydrocannabinol in frequent users of cannabis. Neuropsychopharmacology 2008; 33: 2505-16.
54. Curran HV, Brignell C, Fletcher S, Middleton P, Henry J. Cognitive and subjective dose-response effects of acute oral delta-9- tetrahydrocannabinol (THC) in infrequent cannabis users. Psychopharmacology 2002; 164: 61-70.
55. D'Souza DC, Perry E, MacDougall L, et al. The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: Implications for psychosis. Neuropsychopharmacology 2004; 29: 1558-72.
56. Abel EL. Marihuana and memory: Acquisition or retrieval? Science 1971; 173: 1038-40.
57. Darley CF, Tinklenberg JR, Roth WT, Hollister LE, Atkinson RC. Influence of marijuana on storage and retrieval processes in memory. Memory Cognition 1973; 1: 196-200.
58. van Hell HH, Bossong MG, Jager G, et al. Evidence for involvement of the insula in the psychotropic effects of THC in humans: A double-blind, randomized pharmacological MRI study. Int J Neuropsychopharmacol 2011; 14: 1377-88.
59. Luo F, Wu G, Li Z, Li SJ. Characterization of effects of mean arterial blood pressure induced by cocaine and cocaine methiodide on BOLD signals in rat brain. Magn Reson Med. 2003; 49: 264-270.
60. Gollub RL, Breiter HC, Kantor H, et al. Cocaine decreases cortical cerebral blood flow but does not obscure regional activation in functional magnetic resonance imaging in human subjects. J Cereb Blood Flow Metab. 1998; 18: 724-34.
61. Block RI, O'Leary DS, Hichwa RD, et al. Effects of frequent marijuana use on memory-related regional cerebral blood flow. Pharmacol Biochem Behav 2002; 72: 237-50.
62. Kanayama G, Rogowska J, Pope HG, Gruber SA, Yurgelun-Todd DA. Spatial working memory in heavy cannabis users: a functional magnetic resonance imaging study. Psychopharmacology (Berl) 2004; 176: 239-47.
63. Jager G, Kahn RS, van den Brink W, van Ree JM, Ramsey NF. Long-term effects of frequent cannabis use on working memory and attention: an fMRI study. Psychopharmacology (Berl) 2006; 185: 358-68.
64. Jager G, van Hell HH, De Win MM, et al. Effects of frequent cannabis use on hippocampal activity during an associative memory task. Eur Neuropsychopharmacol 2007; 17: 289-97.
65. Herning RI, Better WE, Tate K, Cadet JL. Cerebrovascular perfusion in marijuana users during a month of monitored abstinence. Neurology. 2005; 64: 488-93.
66. Yücel M, Solowij N, Respondek C, et al. Regional brain abnormalities associated with long-term heavy cannabis use. Arch Gen Psychiatry 2008; 65: 694-701.
67. Ashtari M, Avants B, Cyckowski L, et al. Medial temporal structures and memory functions in adolescents with heavy cannabis use. J Psychiatr Res 2011; 45: 1055-66.
68. Nestor L, Roberts G, Garavan H, Hester R. Deficits in learning and memory: parahippocampal hyperactivity and frontocortical hypoactivity in cannabis users. Neuroimage 2008; 40: 1328-39.
69. Smith AM, Longo CA, Fried PA, Hogan MJ, Cameron I. Effects of marijuana on visuospatial working memory: an fMRI study in young adults. Psychopharmacology (Berl) 2010; 210: 429-38.
70. Schneider M, Koch M. Chronic pubertal, but not adult chronic cannabinoid treatment impairs sensorimotor gating, recognition memory, and the performance in a progressive ratio task in adult rats. Neuropsychopharmacology 2003; 28: 1760-9.
71. Jacobsen LK, Mencl WE, Westerveld M, Pugh KR. Impact of cannabis use on brain function in adolescents. Ann N Y Acad Sci 2004; 1021: 384-90.
72. Mason MF, Norton MI, Van Horn JD, Wegner DM, Grafton ST, Macrae CN. Wandering minds: the default network and stimulusindependent thought. Science 2007; 315: 393-5.
73. Jansma JM, Ramsey NF, de Zwart JA, van Gelderen P, Duyn JH. fMRI study of effort and information processing in a working memory task. Hum Brain Mapp 2007; 28: 431-40.
74. Weissman DH, Roberts KC, Visscher KM, Woldorff MG. The neural bases of momentary lapses in attention. Nat Neurosci 2006; 9: 971-8.
75. Sonuga-Barke EJ, Castellanos FX. Spontaneous attentional fluctuations in impaired states and pathological conditions: a neurobiological hypothesis. Neurosci Biobehav Rev 2007; 31: 977-86.
76. Buckner RL, Andrews-Hanna JR, Schacter DL. The brain's default network: anatomy, function, and relevance to disease. Ann N Y Acad Sci 2008; 1124: 1-38.
77. Jacobsen LK, Pugh KR, Constable RT, Westerveld M, Mencl WE. Functional correlates of verbal memory deficits emerging during nicotine withdrawal in abstinent adolescent cannabis users. Biol Psychiatry 2007; 61: 31-40.
78. Schweinsburg AD, Schweinsburg BC, Cheung EH, Brown GG, Brown SA, Tapert SF. fMRI response to spatial working memory in adolescents with comorbid marijuana and alcohol use disorders. Drug Alcohol Depend 2005 79: 201-10.
79. Schweinsburg AD, Nagel BJ, Schweinsburg BC, Park A, Theilmann RJ, Tapert SF. Abstinent adolescent marijuana users show altered fMRI response during spatial working memory. Psychiatry Res 2008; 163: 40-51.
80. Padula CB, Schweinsburg AD, Tapert SF. Spatial working memory performance and fMRI activation interaction in abstinent adolescent marijuana users. Psychol Addict Behav 2007; 21: 478-87.
81. Schweinsburg AD, Schweinsburg BC, Medina KL, McQueeny T, Brown SA, Tapert SF. The influence of recency of use on fMRI response during spatial working memory in adolescent marijuana users. J Psychoactive Drugs 2010; 42: 401-12.
82. Jager G, Block RI, Luijten M, Ramsey NF. Cannabis Use and Memory Brain Function in Adolescent Boys: A Cross-Sectional Multicenter Functional Magnetic Resonance Imaging Study. J Am Acad Child Adolesc Psychiatry 2010; 49: 561-72.
83. Schweinsburg AD, Schweinsburg BC, Nagel BJ, Eyler LT, Tapert SF. Neural correlates of verbal learning in adolescent alcohol and marijuana users. Addiction 2011; 106: 564-73.
84. Becker B, Wagner D, Gouzoulis-Mayfrank E, Spuentrup E, Daumann J. The impact of early-onset cannabis use on functional brain correlates of working memory. Prog Neuropsychopharmacol Biol Psychiatry 2010; 34: 837-45.
85. Becker B, Wagner D, Gouzoulis-Mayfrank E, Spuentrup E, Daumann J. Altered parahippocampal functioning in cannabis users is related to the frequency of use. Psychopharmacology (Berl) 2010; 209: 361-74.
86. Bhattacharyya S, Atakan Z, Martin-Santos R, et al. Preliminary report of biological basis of sensitivity to the effects of cannabis on psychosis: AKT1 and DAT1 genotype modulates the effects of delta-9-tetrahydrocannabinol on midbrain and striatal function. Mol Psychiatry 2012; 17: 1152-5.
87. Caspi A, Moffitt TE, Cannon M, et al. Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol-O-methyltransferase gene: longitudinal evidence of a gene X environment interaction. Biol Psychiatry 2005; 57: 1117-27.
88. Henquet C, Rosa A, Krabbendam L, et al. An Experimental Study of Catechol-O-Methyltransferase Val(158)Met Moderation of Delta-9-Tetrahydrocannabinol-Induced Effects on Psychosis and Cognition. Neuropsychopharmacology 2006; 31: 2748-57.
89. Manoach DS. Prefrontal cortex dysfunction during working memory performance in schizophrenia: reconciling discrepant findings. Schizophr Res 2003; 60: 285-98.
90. Schwindt GC, Black SE. Functional imaging studies of episodic memory in Alzheimer's disease: a quantitative meta-analysis. Neuroimage 2009; 45: 181-90.
91. Seidenberg M, Guidotti L, Nielson KA, et al. Semantic memory activation in individuals at risk for developing Alzheimer disease. Neurology 2009; 73: 612-20.
92. Woodard JL, Seidenberg M, Nielson KA, et al. Semantic memory activation in amnestic mild cognitive impairment. Brain 2009; 132: 2068-78.
93. Pomarol-Clotet E, Salvador R, Sarro S, et al. Failure to deactivate in the prefrontal cortex in schizophrenia: dysfunction of the default mode network? Psychol Med 2008; 38: 1185-93.
94. Whitfield-Gabrieli S, Thermenos HW, Milanovic S, et al. Hyperactivity and hyperconnectivity of the default network in schizophrenia and in first-degree relatives of persons with schizophrenia. Proc Natl Acad Sci U S A 2009; 106: 1279-84.
95. Fassbender C, Zhang H, Buzy WM, et al. A lack of default network suppression is linked to increased distractibility in ADHD. Brain Res 2009; 1273: 114-28.
96. Peterson BS, Potenza MN, Wang Z, et al. An FMRI study of the effects of psychostimulants on default-mode processing during Stroop task performance in youths with ADHD. Am J Psychiatry 2009; 166: 1286-94.
97. Lustig C, Snyder AZ, Bhakta M, et al. Functional deactivations: change with age and dementia of the Alzheimer type. Proc Natl Acad Sci U S A 2003; 100: 14504-9.
98. Pertwee RG. Ligands that target cannabinoid receptors in the brain: from THC to anandamide and beyond. Addict Biol 2008; 13: 147-59.
99. Bisogno T, Hanus L, De Petrocellis L, et al. Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. Br J Pharmacol 2001; 134: 845-52.
100. Leweke FM, Piomelli D, Pahlisch F, et al. Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Transl Psychiatry 2012; 2: e94.
101. Karniol IG, Shirakawa I, Kasinski N, Pfeferman A, Carlini EA. Cannabidiol interferes with the effects of delta 9 - tetrahydrocannabinol in man. Eur J Pharmacol 1974; 28: 172-7.
102. Zuardi AW, Shirakawa I, Finkelfarb E, Karniol IG. Action of cannabidiol on the anxiety and other effects produced by delta 9-THC in normal subjects. Psychopharmacology (Berl) 1982; 76: 245-50.
103. Bhattacharyya S, Morrison PD, Fusar-Poli P, et al. Opposite effects of delta-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology. Neuropsychopharmacology 2010; 35: 764-74.
104. Morgan CJ, Schafer G, Freeman TP, Curran HV. Impact of cannabidiol on the acute memory and psychotomimetic effects of smoked cannabis: naturalistic study. Br J Psychiatry 2010; 197: 285-90.
105. Morgan CJ, Gardener C, Schafer G, et al. Sub-chronic impact of cannabinoids in street cannabis on cognition, psychotic-like symptoms and psychological well-being. Psychol Med 2011 Jul 29; [Epub ahead of print].
106. Schubart CD, Sommer IE, van Gastel WA, Goetgebuer RL, Kahn RS, Boks MP. Cannabis with high cannabidiol content is associated with fewer psychotic experiences. Schizophr Res 2011; 130: 216-21.
107. Bergamaschi MM, Queiroz RH, Chagas MH, et al. Cannabidiol reduces the anxiety induced by simulated public speaking in treatment- naive social phobia patients. Neuropsychopharmacology 2011; 36: 1219-26.
108. Zuardi AW, Crippa JA, Hallak JE, et al. Cannabidiol for the treatment of psychosis in Parkinson's disease. J Psychopharmacol 2009; 23: 979-83.
109. Bhattacharyya S, Crippa JA, Allen P, et al. Induction of psychosis by _9-tetrahydrocannabinol reflects modulation of prefrontal and striatal function during attentional salience processing. Arch Gen Psychiatry 2012; 69: 27-36.
110. Pijlman FT, Rigter SM, Hoek J, Goldschmidt HM, Niesink RJ. Strong increase in total delta-THC in cannabis preparations sold in Dutch coffee shops. Addict Biol 2005; 10: 171-80.
111. Potter DJ, Clark P, Brown MB. Potency of delta 9-THC and other cannabinoids in cannabis in England in 2005: implications for psychoactivity and pharmacology. J Forensic Sci 2008; 53: 90-4.
112. Mehmedic Z, Chandra S, Slade D, et al. Potency trends of _9-THC and other cannabinoids in confiscated cannabis preparations from 1993 to 2008. J Forensic Sci 2010; 55: 1209-17.
113. Cascini F, Aiello C, Di Tanna G. Increasing delta-9- tetrahydrocannabinol (_-9-THC) content in herbal cannabis over time: systematic review and meta-analysis. Curr Drug Abuse Rev 2012; 5: 32-40.
114. McGorry PD, Nelson B, Amminger GP, et al. Intervention in individuals at ultra-high risk for psychosis: a review and future directions. J Clin Psychiatry 2009; 70: 1206-12.